Average Co-Inventor Count = 3.51
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Incyte Corporation (19 from 665 patents)
2. Incyte Holdings Corporation (10 from 147 patents)
3. Incyte Holdings Comoration (1 from 1 patent)
20 patents:
1. 12226418 - Dosing regimen for the treatment of PI3K related disorders
2. 12226419 - Topical formulation for a JAK inhibitor
3. 12150943 - JAK1 pathway inhibitors for the treatment of gastrointestinal disease
4. 12151026 - Sustained release dosage forms for a JAK1 inhibitor
5. 11896717 - Sustained-release dosage forms of ruxolitinib
6. 11628162 - Methods of treating cancer with an FGFR inhibitor
7. 11596632 - JAK1 pathway inhibitors for the treatment of gastrointestinal disease
8. 11590136 - Topical formulation for a JAK inhibitor
9. 11576865 - Sustained-release dosage forms of ruxolitinib
10. 11576864 - Sustained-release dosage forms of ruxolitinib
11. 11571425 - Topical formulation for a JAK inhibitor
12. 11337927 - Sustained-release dosage forms of ruxolitinib
13. 11219624 - Topical formulation for a JAK inhibitor
14. 11045421 - Sustained release dosage forms for a JAK1 inhibitor
15. 10874616 - Sustained-release dosage forms of ruxolitinib